Ribosomal protein L7 pseudogene 20 (RPL7P20)

RPL7P20 is a processed pseudogene derived from the ribosomal protein L7 (RPL7) gene, part of the L30P family of large ribosomal subunit proteins[1][2][6]. Pseudogenes like RPL7P20 are abundant in the human genome and originate from retrotransposition events, resulting in truncated, non-functional copies of the parent gene that are generally not transcribed into functional protein[6]. While the functional RPL7 protein plays roles in protein synthesis, ribosome biogenesis, and has been studied in immune and viral contexts[1][2][3], its pseudogenes, including RPL7P20, do not produce active proteins and are not considered molecular targets for therapeutic intervention. RPL7P20 is not a receptor, enzyme, transporter, or any other target class but is a non-functional genetic element, making it not a therapeutic target[6]. It is a result of gene duplication/retrotransposition; pseudogenes like RPL7P20 lack coding capacity and typically have no biological function or disease association[6]. There are multiple RPL7 pseudogenes with similar nomenclature for different loci (e.g., RPL7P7, RPL7P13, etc.), none of which are functional or valid therapeutic targets[4]. Any potential confusion may occur from mistaking RPL7P20 for the functional RPL7, which is a bona fide ribosomal protein with well-characterized roles in cellular biology and disease[1][2][3]. RPL7P20 itself should not be considered as a molecular target for drug discovery, biomarker development, or disease studies. Any information regarding drug interaction, mechanism of action, biological function, or disease association would apply only to the parental RPL7, not the RPL7P20 pseudogene. This entity is incorrect as a therapeutic target[6]. If you require information on the active protein, refer to Ribosomal protein L7 (RPL7), not the pseudogene.

Other names

RPL7P20RPL7_8_636ribosomal protein L7 pseudogene 20